ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

3:00PM-4:30PM: Abstract Number: 1586

Sustained Remission Following the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis (XANADU Study): A Multicenter, Prospective, and Randomized Controlled Study

Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies

3:00PM-4:30PM: Abstract Number: 1600

The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Abstracts: Spondyloarthritis Including PsA – Treatment II: PsA

3:00PM-4:30PM: Abstract Number: 1596

The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes II: Complications

3:00PM-4:30PM: Abstract Number: 1579

The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography

Abstracts: Metabolic and Crystal Arthropathies – Basic and Clinical Science

4:30PM-6:00PM: Abstract Number: 1606

An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis

Abstracts: RA – Treatment II: Pre- and Early Disease

4:30PM-6:00PM: Abstract Number: 1610

Are Serological Protease-mediated Peptides of Tissue Remodeling and Inflammation the New Disease Activity Biomarkers in Psoriatic Arthritis Patients?

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes I: Diagnosis and Disease Activity

4:30PM-6:00PM: Abstract Number: 1618

Combined Orbital and Cranial Vessel Wall MRI for Diagnosis and Longitudinal Monitoring of Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders I

4:30PM-6:00PM: Abstract Number: 1609

Comorbidity Clusters in Ankylosing Spondylitis and Their Association with Disease Activity and Functional Impairment: Data from the PSOAS Cohort

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes I: Diagnosis and Disease Activity

4:30PM-6:00PM: Abstract Number: 1613

Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Nested Matched Cohort Study from Within the UK National Early Inflammatory Arthritis Audit

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes I: Diagnosis and Disease Activity

4:30PM-6:00PM: Abstract Number: 1617

Direct Comparison of Ultrasound, [18F]Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging: Early Diagnostics in Patients Suspected of Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders I

4:30PM-6:00PM: Abstract Number: 1616

Drug Use and Pregnancy Outcomes in Pregnant Women with Systemic Vasculitis: A Nation Wide Cohort Study

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders I

4:30PM-6:00PM: Abstract Number: 1614

Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes I: Diagnosis and Disease Activity

4:30PM-6:00PM: Abstract Number: 1604

Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial

Abstracts: RA – Treatment II: Pre- and Early Disease

4:30PM-6:00PM: Abstract Number: 1603

Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial

Abstracts: RA – Treatment II: Pre- and Early Disease

4:30PM-6:00PM: Abstract Number: 1607

Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis

Abstracts: RA – Treatment II: Pre- and Early Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].